NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $161.80 +1.31 (+0.81%) As of 12:21 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novartis Stock (NYSE:NVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novartis alerts:Sign Up Key Stats Today's Range$161.49▼$163.2750-Day Range$137.22▼$164.9852-Week Range$123.24▼$170.46Volume745,782 shsAverage Volume2.00 million shsMarket Capitalization$308.75 billionP/E Ratio30.87Dividend Yield1.90%Price Target$152.25Consensus RatingHold Company Overview Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments. Novartis was formed in 1996 through the merger of Swiss companies Ciba-Geigy and Sandoz. In 2023, it completed the spin-off of its generics and biosimilars business, Sandoz, and now focuses on innovative medicines. Headquartered in Basel, Switzerland, Novartis serves patients and healthcare systems in markets around the world.AI Generated. May Contain Errors. Read More Novartis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreNVS MarketRank™: 3.105688900675 of 5 starsNovartis scored higher than 62% of companies evaluated by MarketBeat, and ranked 327th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 6 buy ratings, 9 hold ratings, and 3 sell ratings.Downside RiskNovartis has a consensus price target of $152.25, representing about 5.7% downside from its current price of $161.50.Amount of Analyst CoverageNovartis has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novartis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth9.78% Earnings GrowthEarnings for Novartis are expected to grow by 9.78% in the coming year, from $9.10 to $9.99 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 30.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 30.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.45.Price to Earnings Growth RatioNovartis has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.24% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 1.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 19.15%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 1.92%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 58.78%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 30.83% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. News and Social Media2.2 / 5News Sentiment0.52 News SentimentNovartis has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Novartis this week, compared to 10 articles on an average week.Search InterestOnly 6 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by Insiders0.01% of the stock of Novartis is held by insiders.Percentage Held by Institutions13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVS Stock News HeadlinesNovartis Wins Positive CHMP Opinion For Cosentyx In Adolescent Hidradenitis SuppurativaNovember 14 at 8:57 AM | rttnews.comNovartis Stock Gets Weaker EPS Estimate from Zacks ResearchNovember 14 at 2:29 AM | americanbankingnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 16 at 1:00 AM | Porter & Company (Ad)Novartis (NVS) Stock Forecast & Price TargetNovember 13 at 1:34 PM | tipranks.comNovartis FY2026 Earnings Forecast Boosted by Zacks ResearchNovember 13 at 1:29 AM | americanbankingnews.comNovartis' Ianalumab Shows Continued Benefits In Two-Year Sjögren's StudyNovember 10, 2026 | rttnews.comFDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene TherapyNovember 7, 2026 | rttnews.comNovartis confirms Zolgensma caused tumors in two children via gene therapy vector integrationNovember 5, 2026 | msn.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $137.87 at the beginning of 2026. Since then, NVS stock has increased by 17.1% and is now trading at $161.4950. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) released its quarterly earnings data on Tuesday, October, 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.21. The business's revenue for the quarter was up 4.4% on a year-over-year basis. Read the conference call transcript. Does Novartis have any subsidiaries? The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. Who are Novartis' major shareholders? Novartis' top institutional shareholders include Fisher Asset Management LLC (0.88%), Cullen Capital Management LLC (0.10%), Dodge & Cox (0.04%) and First Trust Advisors LP (0.02%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), NVIDIA (NVDA), AbbVie (ABBV), Intel (INTC) and Cisco Systems (CSCO). Company Calendar Last Earnings10/27/2026Today11/16/2026Meet Novartis Management 2026 Part 111/19/2026Meet Novartis Management 2026 Part 211/19/2026Meet Novartis Management 2026 Part 311/19/2026Fiscal Year End12/31/2026Next Earnings (Estimated)2/03/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NVS's financial health is in the Green zone, according to TradeSmith. NVS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVS CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees75,267Year Founded1996Price Target and Rating Average Price Target for Novartis$152.25 High Price Target$180.00 Low Price Target$130.00 Potential Upside/Downside-5.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$5.24 Trailing P/E Ratio30.91 Forward P/E Ratio16.19 P/E Growth2.94Net Income$13.98 billion Net Margins18.11% Pretax Margin22.83% Return on Equity41.04% Return on Assets14.45% Debt Debt-to-Equity Ratio0.98 Current Ratio0.88 Quick Ratio0.70 Sales & Book Value Annual Sales$54.53 billion Price / Sales5.66 Cash Flow$10.83 per share Price / Cash Flow14.94 Book Value$22.04 per share Price / Book7.34Miscellaneous Outstanding Shares1,908,150,000Free Float1,907,961,000Market Cap$308.69 billion OptionableOptionable Beta0.40 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:NVS) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.